A new study published in Pharmaceuticals and conducted by researchers from McGill University sheds light on how cannabidiol (CBD) may exert anti-cancer effects in a particularly aggressive form of leukemia.
The study focused on acute lymphoblastic leukemia of pre-T cell origin (T-ALL), a fast-growing blood cancer known for its resistance to many conventional therapies. While prior research has shown that CBD can kill various cancer cells, the precise mechanisms behind these effects have remained unclear.
Using Jurkat leukemia cells in controlled laboratory conditions, the researchers found that CBD significantly reduced the expression of CD47, a surface protein often described as a “don’t eat me” signal that helps cancer cells evade destruction by the immune system. Lowering CD47 expression makes these cells more vulnerable to immune clearance.
At the same time, CBD triggered apoptosis, a form of programmed cell death, in the leukemia cells. The team tested whether this effect was tied to the body’s cannabinoid receptors, but found that neither activating nor blocking the CB2 receptor altered CBD’s impact. Blocking anion channels also had no effect.
Instead, the researchers discovered that the key mechanism involved a protein called Voltage-Dependent Anion Channel 1 (VDAC-1). When a VDAC-1 oligomerization inhibitor was introduced, the CBD-induced reduction in CD47 and the resulting apoptosis were significantly reversed. This indicates that CBD’s anti-leukemia action in this model depends heavily on VDAC-1 activity rather than traditional cannabinoid receptor pathways.
The study also examined CBD’s effects on healthy primary human CD4+ T cells. Although similar reductions in CD47 and increases in apoptosis were observed, the effects were less pronounced than in leukemia cells. Still, the researchers caution that this finding is important, suggesting that CBD’s impact on healthy immune cells should be carefully monitored if it is used as an adjunct cancer therapy.
Overall, the findings suggest that CBD may help expose leukemia cells to immune attack while simultaneously triggering their self-destruction through a previously underexplored cellular pathway. The researchers say this dual mechanism could make CBD a promising candidate for further investigation as an adjuvant or neoadjuvant therapy in blood cancers, while emphasizing the need for additional research to assess safety and effectiveness in clinical settings.
Sponsored
